spacer
home > ebr > spring 2018 > redefining proteomics
PUBLICATIONS
European Biopharmaceutical Review

Redefining Proteomics

Tumour suppressor p53 (TP53) is a gene, not a protein. It is rhetorically convenient but scientifically inaccurate to suggest these are morphological variants of the same thing. Human cells splice and assemble in at least nine different ways the exons present in the TP53 gene. Therefore, TP53 isoform 7 is the appropriate name for an mRNA intermediary between gene and protein. Likewise, protein does not simply swap ribonucleotides for amino acids at a 3:1 ratio.

Many residues will be variously and reversibly modified with chemical, carbohydrate, lipidatious, and/or proteinacious adducts that will impart different structures and biochemical properties; direct the protein to different locations; alter activities, functions, and interactions; and control destruction of the molecule itself – all as the larger cell sees fit. These co- and post-translational modifications (PTM) are essential to everything about proteins that makes them so. Methylated, phospho-TP53 isoform 7 is thus a protein. If a proteomic screen is not providing this level of information, is it technically even proteomic?

Mass Spectrometry: Necessary but Insufficient

Stable proteins may have no concurrently existing, corresponding mRNA. Post-transcriptional regulation means not all mRNA present within cells has such corresponding protein. To identify the protein components of a complex sample, no substitute for mass spectrometry (MS) exists, particularly in targeted approaches where one seeks to identify the presence of a particular component within complex mixtures

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Christian Loch is Chief Executive and Science Officer at AVMBioMed. He is also adjunct faculty in the Department of Chemistry at Villanova University, US, where he teaches proteomics in the graduate school. Christian has 10 years of industry experience and holds an MPH in epidemiology from the University of Washington, US, and a PhD in biochemistry from the University of Virginia, US.
spacer
Dr Christian Loch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

c-LEcta signs Europe sales and distribution agreement with VWR for c-LEcta’s DENARASE®

• DENARASE® is now available through VWR’s sales channels in Europe • VWR, part of Avantor, is a leading global provider of product and service solutions to laboratory and production customers • Cooperation harbors the potential for c-LEcta’s product to gain additional share in a highly dynamic market
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement